Raymond James Financial Services Advisors’s Actinium Pharmaceuticals ATNM Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,400	Closed	-$8K	–	2827
2020 Q1	$8K	Sell	1,400 -7	-0.5%	-$50	﹤0.01%	2398
2019 Q4	$9K	Buy	1,407 +834	+146%	+$5.75K	﹤0.01%	2830
2019 Q3	$4K	Hold	573	–	–	﹤0.01%	2793
2019 Q2	$4K	Hold	573	–	–	﹤0.01%	2836
2019 Q1	$8K	Hold	573	–	–	﹤0.01%	2777
2018 Q4	$7K	Hold	573	–	–	﹤0.01%	2549
2018 Q3	$13K	Hold	573	–	–	﹤0.01%	2780
2018 Q2	$11K	Hold	573	–	–	﹤0.01%	2748
2018 Q1	$6K	Sell	573 -267	-32%	-$4.54K	﹤0.01%	2532
2017 Q4	$17K	Buy	840 +233	+38%	+$4.69K	﹤0.01%	2497
2017 Q3	$10K	Hold	607	–	–	﹤0.01%	2542
2017 Q2	$22K	Hold	607	–	–	﹤0.01%	2459
2017 Q1	$27K	Buy	607 +34	+6%	+$1.3K	﹤0.01%	2347
2016 Q4	$15K	Hold	573	–	–	﹤0.01%	2314
2016 Q3	$23K	Hold	573	–	–	﹤0.01%	2243
2016 Q2	$30K	Buy	573 +6	+1%	+$335	﹤0.01%	2199
2016 Q1	$34K	Buy	+567	New	+$35.8K	﹤0.01%	1994

Other funds holding ATNM

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Raymond James Financial Services Advisors's ATNM Position: Q2 2020 in Review

Raymond James Financial Services Advisors sold out of Actinium Pharmaceuticals (ATNM) in Q2 2020, closing a stake of 1,400 shares — an estimated $8K sold.

Raymond James Financial Services Advisors first reported a position in ATNM in Q1 2016 and held it in 17 quarters. The position peaked at $34K in Q1 2016. 59 funds tracked by Wall St. Rank hold ATNM as of Q2 2020.

Raymond James Financial Services Advisors reported no remaining Actinium Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Raymond James Financial Services Advisors sold 1,400 Actinium Pharmaceuticals shares in Q2 2020, an estimated $8K.
Raymond James Financial Services Advisors first reported a position in Actinium Pharmaceuticals in Q1 2016 and held it in 17 quarters.
Raymond James Financial Services Advisors's Actinium Pharmaceuticals position peaked at $34K in Q1 2016.
59 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2020.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2020, filed 17 Jul 2020.